US Patent No: 7,700,604

Number of patents in Portfolio can not be more than 2000

Hydantoin derivatives as metalloproteinase inhibitors

Stats

ALSO PUBLISHED AS: 20080032997
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ASTRAZENECA ABSODERTALJE1223

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Af, Rosenschold Magnus Munck Lund, SE 7 50
Gabos, Balint - 28 90
Lundkvist, Michael Lund, SE 20 140
Shamovsky, Igor Lund, SE 8 34
Zlatoidsky, Pavol Lund, SE 18 133

Cited Art

Patent Info (Count) # Cites Year
 
ASTRAZENECA AB (20)
7,368,465 Metalloproteinase inhibitors 11 2002
7,427,631 Metalloproteinase inhibitors 12 2002
7,132,434 Metalloproteinase inhibitors 11 2002
7,354,940 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 11 2003
2006/0063,818 Hydantoin derivatives and deren verwendung als tace inhibitoren 15 2003
2004/0147,573 Metalloproteinase inhibitors 23 2003
2004/0106,659 Metalloproteinase inhibitors 15 2004
2004/0110,809 Metalloproteinase inhibitors 16 2004
2004/0116,486 Metalloproteinase inhibitors 16 2004
2005/0256,176 Sulphonamide derivatives and their use as tace inhibitors 15 2005
2008/0004,317 Compounds 11 2005
2008/0064,710 Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases 11 2005
2008/0032,997 Novel Hydantoin Derivatives as Metalloproteinase Inhibitors 11 2005
2008/0293,743 Novel Hydantoin Derivatives as Metalloproteinase Inhibitors 11 2005
2006/0276,524 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 14 2006
2009/0054,659 Process to Prepare Sulfonyl Chloride Derivatives 9 2007
2008/0171,882 Metalloproteinase Inhibitors 10 2007
2008/0221,139 Novel Compounds 11 2007
2008/0262,045 Metalloproteinase Inhibitors 11 2008
2008/0306,065 Metalloproteinase Inhibitors 11 2008
 
BRISTOL-MYERS SQUIBB PHARMA COMPANY (4)
6,268,379 Substituted aryl hydroxamic acids as metalloproteinase inhibitors 23 1999
6,429,213 Cyclic hydroxamic acids as metalloproteinase inhibitors 37 1999
6,890,915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) 13 2002
6,906,053 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) 13 2004
 
WARNER-LAMBERT COMPANY (3)
5,246,943 Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties 48 1992
5,308,853 Substituted-5-methylidene hydantoins with AT.sub.1 receptor antagonist properties 18 1992
5,919,790 Hydroxamate inhibitors of interleukin-1.beta. converting enzyme 23 1997
 
DARWIN DISCOVERY LIMITED (2)
6,048,841 Peptidyl compounds 15 1996
5,955,435 Peptidyl compounds having MMP and TNF inhibitory activity 15 1997
 
GPI NIL HOLDINGS, INC. (2)
6,339,101 N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders 14 1998
7,078,424 N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres 13 2003
 
PFIZER PRODUCTS INC. (2)
6,114,361 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives 23 1999
2004/0266,832 Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfo-nyl pyridine 9 2004
 
ABBOTT LABORATORIES (1)
2002/0091,107 Oxazolidinone antibacterial agents 12 2001
 
AU OPTRONICS CORP. (1)
2005/0019,994 [METHOD OF FABRICATING POLYSILICON FILM] 15 2004
 
BRISTOL-MYERS SQUIBB COMPANY (1)
2002/0065,219 Water soluble thiazolyl peptide derivatives 14 2001
 
CAMBREX CORPORATION, A DE CORP. (1)
4,983,771 Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid 11 1989
 
EURO-CELTIQUE S.A. (1)
6,166,041 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma 26 1997
 
HOECHST AKTIENGESELLSCHAFT (1)
6,159,995 Substituted diaminocarboxylic acids 28 1998
 
HOFFMANN-LA ROCHE INC. (1)
6,291,685 Methods for the preparation of 4-hydroxybenzothiophene 18 2000
 
JANSSEN PHARMACEUTICA N.V. (1)
5,521,187 1,3-Dihydro-2H-imidazo[4,5-B]quinolin-2-one derivatives 16 1994
 
LILLY INDUSTRIES LIMITED (1)
4,241,073 Treatment of immediate hypersensitivity diseases with aryl hydantoins 20 1979
 
MITSUI TOATSU CHEMICALS, INC. (1)
5,068,187 Process for producing D-.alpha.-amino acids 15 1989
 
NOVARTIS AG (1)
6,277,987 Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives 19 1999
 
NOVO NORDISK A/S (1)
6,046,214 Heterocyclic compounds 17 1998
 
PHARMACIA & UPJOHN COMPANY (1)
5,804,593 .alpha.-Amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors 35 1997
 
PHARMACIA & UPJOHN S.P.A. (1)
6,218,418 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents 22 2000
 
SCIENCE UNION ET CIE (1)
4,315,031 Thiosubstituted amino acids 17 1978
 
THE PROCTER & GAMBLE COMPANY (1)
6,329,418 Substituted pyrrolidine hydroxamate metalloprotease inhibitors 14 1999
 
WYETH HOLDINGS CORPORATION (1)
6,340,691 Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors 16 2000
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (2)
2002/0006,920 Arylsulfonylamino hydroxamic acid derivatives 13 2001
2005/0171,096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) 16 2005

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
ASTRAZENECA AB (3)
8,183,251 Hydantoin compounds and pharmaceutical compositions thereof 0 2007
7,989,620 Hydantoin derivatives for the treatment of obstructive airway diseases 0 2009
8,153,673 Metalloproteinase inhibitors 0 2010

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Oct 20, 2013
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 20, 2017
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 20, 2021
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00